Cited by 132Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity

Jansen, Aaron P., Camalier, Corinne E., Stark, Cristi, Colburn, Nancy H.·2004·Molecular Cancer Therapeutics

Open this paper in CoChat — free account

Abstract

Programmed cell death 4 (Pdcd4), originally identified as an inhibitor of murine cellular transformation, inhibits protein synthesis by directly interacting with eukaryotic initiation factor 4A (eIF4A) of the translation initiation complex. The relevance of Pdcd4 to a broad range of human cancers derived from multiple tissue sites is unknown. Protein expression patterns from the National Cancer Institute drug-screening panel of 60 human cancer cells (NCI60) were analyzed by Western blot methods and revealed frequent reduction of Pdcd4 protein levels in renal-, lung-, and glia-derived tumors. Greater than mean Pdcd4 protein levels correlated with the antitumor activity of geldanamycin and tamoxifen. Stable expression of antisense PDCD4 significantly reduced the sensitivity of MCF-7 breast cancer cells to geldanamycin and to tamoxifen. Sensitivity to geldanamycin significantly increased in UO-31 renal cancer cells expressing sense PDCD4 cDNA. Increased geldanamycin sensitivity was accompanied by enhanced cell cycle arrest and apoptosis. One primary mode of inactivation of Pdcd4 in human cancers appears to involve down-regulated expression, and this down-regulation causes a decreased sensitivity to geldanamycin cytotoxicity. Thus, up-regulating Pdcd4 expression may be promising for geldanamycin-based combination therapy.

Integrity signals

Registry

Crossref · 10.1158/1535-7163.103.3.2

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
Monks, A. P., Scudiero, D. A., Skehan, P., Shoemaker, R. H., Paull, K. D., Vistica, D. T., Hose, C. D., Langley, J. W., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,305
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,858
Tumor Suppressor Genes
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,765
Regulation of matrix metalloproteinase expression in tumor invasion
Westermarck, J. K., & Kähäri, V. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.781 · Cited by 1,494
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M. C., Smith, L. H., Lee, J. K., Tanabe, L. K., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A. P., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 970
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 778
The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation
Yang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494
Self-citation
Polyubiquitination and Proteasomal Degradation of the p185c-B-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation
Venkatachalam, S., Shi, Y., Jones, S. N., Vogel, H. S., Bradley, A., Pinkel, D., & Donehower, L. A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4657 · Cited by 449
Let Me Count the Ways
Walther, J. B., Loh, T., & Granka, L. A. (2005) · Journal of Language and Social Psychology · doi:10.1177/0261927x04273036 · Cited by 436
Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion
Young, M. R., Li, J. J., Rincón, M., Flavell, R. A., Sathyanarayana, B. K., Hunziker, R., & Colburn, N. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9827 · Cited by 387
Self-citation
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee, J. S., Paull, K. D., Alvarez, M., Hose, C. D., Monks, A., Grever, M. R., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
eIF4E expression in tumors: its possible role in progression of malignancies
Benedetti, A. D., & Harris, A. L. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00132-0 · Cited by 331
BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
Gorre, M. E., Ellwood‐Yen, K., Chiosis, G., Rosen, N. X., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 279
The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
An, W. G., Schulte, T. W., & Neckers, L. Μ. (2000) · PubMed · Cited by 265
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis
Chen, Y., Knösel, T., Kristiansen, G., Pietas, A., Garber, M. E., Matsuhashi, S., Ozaki, I., & Petersen, I. (2003) · The Journal of Pathology · doi:10.1002/path.1378 · Cited by 265
Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation
Cmarik, J. L., Min, H., Hegamyer, G., Zhan, S., Kulesz-Martin, M., Yoshinaga, H., Matsuhashi, S., & Colburn, N. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14037 · Cited by 254
Self-citation
Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death
Shibahara, K., Asano, M., Ishida, Y., Aoki, T., Koike, T., & Honjo, T. (1995) · Gene · doi:10.1016/0378-1119(95)00607-9 · Cited by 223
Geldanamycin-Induced Destabilization of Raf-1 Involves the Proteasome
Schulte, T. W., An, W. G., & Neckers, L. Μ. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7527 · Cited by 188
A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation
Yang, H.-S., Jansen, A. P., Nair, R., Shibahara, K., Verma, A. K., Cmarik, J. L., & Colburn, N. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204137 · Cited by 185
Self-citation
Tumor suppressor genes
Macleod, K. F. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00041-6 · Cited by 180
Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data.
Paull, K. D., Lin, C. M., Malspeis, L., & Hamel, E. (1992) · PubMed · Cited by 171
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
Monks, A. P., Da, S., Johnson, G. S., Paull, K. D., & Sausville, E. (1997) · PubMed · Cited by 171
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation
Yang, H.-S., Knies, J. L., Stark, C., & Colburn, N. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206433 · Cited by 160
Self-citation
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
Münster, P. N., Srethapakdi, M., Moasser, M. M., & Rosen, N. X. (2001) · PubMed · Cited by 145
Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo
Whitesell, L. J., Sutphin, P. D., An, W. G., Schulte, T. W., Blagosklonny, M. V., & Neckers, L. (1997) · Oncogene · doi:10.1038/sj.onc.1201120 · Cited by 127
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 126
Haplo-insufficiency? Let me count the ways: Figure 1.Preprint
Quon, K. C., & Berns, A. J. M. (2001) · Genes & Development · doi:10.1101/gad.949001 · Cited by 109
Differential Transcriptional Regulation of CD161 and a Novel Gene, 197/15a , by IL-2, IL-15, and IL-12 in NK and T Cells
Azzoni, L., Zatsepina, O., Abebe, B., Bennett, I. M., Kanakaraj, P., & Perussia, B. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3493 · Cited by 105
Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex
Shiotsu, Y., Neckers, L. Μ., Wortman, I. A., An, W. G., Schulte, T. W., Soga, S., Murakata, C., Tamaoki, T., & Akinaga, S. (2000) · Blood · doi:10.1182/blood.v96.6.2284 · Cited by 102
Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers
Niedermeyer, J., Scanlan, M. J., Garin‐Chesa, P., Daiber, C., Fiebig, H., Old, L. J., Rettig, W. J., & Schnapp, A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970502)71:3 · Cited by 91
Flow cytometric analysis of G1‐ and G2/M‐phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements
Nüsse, M., Beisker, W., Hoffmann, C., & Tárnok, A. (1990) · Cytometry · doi:10.1002/cyto.990110707 · Cited by 88
The Role of the Matrix Metalloproteinase Stromelysin in the Progression of Squamous Cell Carcinomas
Matrisian, L. M., McDonnell, S., Miller, D. B., Navre, M., Seftor, E. A., & Hendrix, M. J. C. (1991) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199109000-00008 · Cited by 70
Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma
Bauer, C., Diesinger, I., Brass, N., Steinhart, H., Iro, H., & Meese, E. U. (2001) · Cancer · doi:10.1002/1097-0142(20010815)92:4 · Cited by 70
Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti‐H731 antibody
Yoshinaga, H., Matsuhashi, S., Fujiyama, C., & Masaki, Z. (1999) · Pathology International · doi:10.1046/j.1440-1827.1999.00995.x · Cited by 62
Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen
Boyd, M. R., Paull, K. D., & Rubinstein, L. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3492-1_2 · Cited by 60
Up-regulation of PDCD4 in senescent human diploid fibroblasts
Kang, M.-J., Ahn, H.-S., Lee, J.-Y., Matsuhashi, S., & Park, W.-Y. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00264-4 · Cited by 57
The Steroid/Thyroid Hormone Receptor Family and Gene Regulation
(1989) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-5466-5 · Cited by 50
Cloning of the TIS gene suppressed by topoisomerase inhibitors
Onishi, Y., Hashimoto, S., & Kizaki, H. (1998) · Gene · doi:10.1016/s0378-1119(98)00313-8 · Cited by 47
Molecular Cloning of the Genes Suppressed in RVC Lymphoma Cells by Topoisomerase Inhibitors
Onishi, Y., & Kizaki, H. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1609 · Cited by 34
Do Receptor-Associated Nuclear Proteins Explain Earliest Steps of Steroid Hormone Function?
Baulieu, E. E., Binart, N., Cadepond, F., CATELLI, M. G., Chambraud, B., Garnier, J., Gasc, J., Schweizer-Groyer, G., Rafestin-Oblin, M. E., Radanyi, C., et al. (1989) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-5466-5_22 · Cited by 17
Untitled work
(2001) · doi:10.1002/1098-1128(200103)21:2

Research works printed but not linked: 1

Matsuhashi S, Yoshinaga H, Yatsuki H, Tsugita A, Hori K. Isolation of a novel gene from a human cell line with Pr-28 MAb which recognizes a nuclear antigen involved in the cell cycle. Res Commun Biochem Cell Mol Biol, 1997;1:109–20.

Sorted by citations

Programmed Cell Death 4 (PDCD4) Is an Important Functional Target of the MicroRNA miR-21 in Breast Cancer Cells
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707224200 · Cited by 1,141
miR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987
MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior
Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., Calin, G. A., Volinia, S., Liu, C., Scarpa, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5194 · Cited by 775
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711
Self-citation
MicroRNA 29b functions in acute myeloid leukemia
Garzon, R., Heaphy, C. E. A., Havelange, V., Fabbri, M., Volinia, S., Tsao, T., Zanesi, N., Kornblau, S. M., Marcucci, G., Calin, G. A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211938 · Cited by 473

See all 132

Authors: Jansen, A. P., Camalier, C. E., Stark, C., & Colburn, N. H.
Affiliations: Frederick National Laboratory for Cancer Research (US)
Venue: Molecular Cancer Therapeutics
Publisher: American Association for Cancer Research (AACR)
Published: 2004-02-01
Volume: 3
Issue: 2
Pages: 103-110
ISSN: 1535-7163 (ISSN-L)
1538-8514
DOI: 10.1158/1535-7163.103.3.2
OpenAlex: W2257484201
Cited by: 132
References: 46
Citations by year: 2025: 2 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 9
FWCI: 3.36
Type: journal article
Language: en
Open access: closed
Locations: Molecular Cancer Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: PDCD4, eIF4A, translation initiation, drug sensitivity, geldanamycin, tamoxifen, kidney cancer, breast cancer, apoptosis, cell cycle arrest, combination therapy, tumor suppressor
MeSH terms: Antineoplastic Agents, Cell Division, Drug Screening Assays, Antitumor, Humans, Kidney Neoplasms, Mitosis, Neoplasms, Prognosis, Quinones, RNA, Messenger, Tamoxifen, Retinoblastoma Protein, G2 Phase, Benzoquinones, Tacrolimus, RNA-Binding Proteins, Cell Line, Tumor, Lactams, Macrocyclic, Apoptosis Regulatory Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks